Sign in Subscribe

targeted-therapy

A collection of 105 issues

Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRC A single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the

CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase

Skip to content The CRC Digest ◇ RESEARCH CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase Genome-wide CRISPR screens identified SMARCAL1 as a key modulator of WRN dependency in MSI-H colorectal cancer, with loss of SMARCAL1 rendering cells resistant to the WRN inhibitor HRO761. The findings shed light on

Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy

Skip to content The CRC Digest ◇ RESEARCH Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy Liquid biopsy detected concurrent Y96S and Y96C mutations in a patient with KRAS G12C-mutated metastatic CRC who progressed after 9.3 months of KRAS G12C inhibitor monotherapy; these polyclonal alterations were

Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer

Skip to content The CRC Digest ▸ TREATMENT Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer A multicentre study followed patients treated with bevacizumab combined with chemoradiation before surgery for locally advanced rectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute

BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology) This

Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer

Skip to content The CRC Digest Precision oncology strategies beyond RAS and RAF in MSS colorectal cancer Review outlines next-generation precision approaches for microsatellite-stable tumors, including antibody-drug conjugates, bispecific antibodies, DNA damage response targeting, and tumor microenvironment-directed therapies. (ESMO Open) This content is informational only and does not constitute medical

CRC Research Finding

Skip to content The CRC Digest ◇ Review examines anti-VEGF plus checkpoint inhibitor combinations in GI cancers A narrative review synthesizes preclinical and clinical data on combining anti-VEGF agents with immune checkpoint inhibitors across gastrointestinal cancers, including colorectal cancer, with emphasis on optimal sequencing strategies. (Discov Oncol) This content is informational

CRC Research Finding

Skip to content The CRC Digest ▸ Meta-Analysis Confirms Targeted Therapy Benefits for Colorectal Cancer Liver Metastases A systematic review and meta-analysis evaluated targeted therapy in colorectal cancer liver metastases, examining overall survival, progression-free survival, objective response rate, and conversion to resection. The analysis provides comprehensive evidence on the role of

Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to